262 related articles for article (PubMed ID: 33640713)
21. Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis.
Liu X; Guo CY; Tou FF; Wen XM; Kuang YK; Zhu Q; Hu H
Int J Cancer; 2020 Jul; 147(1):116-127. PubMed ID: 31633798
[TBL] [Abstract][Full Text] [Related]
22. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.
Bylicki O; Barazzutti H; Paleiron N; Margery J; Assié JB; Chouaïd C
BioDrugs; 2019 Apr; 33(2):159-171. PubMed ID: 30825132
[TBL] [Abstract][Full Text] [Related]
23. Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
Gelsomino F; Di Federico A; Filippini DM; Dall'Olio FG; Lamberti G; Sperandi F; Balacchi C; Brocchi S; Ardizzoni A
Clin Lung Cancer; 2020 Mar; 21(2):e45-e48. PubMed ID: 31902695
[No Abstract] [Full Text] [Related]
24. [Checkpoint Inhibitors in the Treatment of Upper Gastrointestinal Tract Tumors].
Obermannova R
Klin Onkol; 2017; 30(Supplementum3):50-54. PubMed ID: 29239193
[TBL] [Abstract][Full Text] [Related]
25. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
26. The therapeutic impact of programmed death - 1 in the treatment of colorectal cancer.
Sangani PS; Yazdani S; Khalili-Tanha G; Ghorbani E; Al-Hayawi IS; Fiuji H; Khazaei M; Hassanian SM; Kiani M; Ghayour-Mobarhan M; Ferns GA; Nazari E; Avan A
Pathol Res Pract; 2024 Jul; 259():155345. PubMed ID: 38805760
[TBL] [Abstract][Full Text] [Related]
27. The safety and efficacy of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of previously treated, advanced gastric or gastro-oesophageal junction cancer: A meta-analysis of prospective clinical trials.
Ni X; Xing Y; Sun X; Suo J
Clin Res Hepatol Gastroenterol; 2020 Apr; 44(2):211-222. PubMed ID: 31208922
[TBL] [Abstract][Full Text] [Related]
28. PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer.
Zhu H; Du C; Yuan M; Fu P; He Q; Yang B; Cao J
Drug Discov Today; 2020 Sep; 25(9):1762-1771. PubMed ID: 32663441
[TBL] [Abstract][Full Text] [Related]
29. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
31. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.
Goleva E; Lyubchenko T; Kraehenbuehl L; Lacouture ME; Leung DYM; Kern JA
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):630-638. PubMed ID: 33716146
[TBL] [Abstract][Full Text] [Related]
32. PD1/PD-L1 Axis in Uro-oncology.
Junker K; Eckstein M; Fiorentino M; Montironi R
Curr Drug Targets; 2020; 21(13):1293-1300. PubMed ID: 32213156
[TBL] [Abstract][Full Text] [Related]
33. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
[TBL] [Abstract][Full Text] [Related]
34. Resistance mechanisms to checkpoint inhibitors.
Weiss SA; Sznol M
Curr Opin Immunol; 2021 Apr; 69():47-55. PubMed ID: 33676271
[TBL] [Abstract][Full Text] [Related]
35. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
Shien K; Papadimitrakopoulou VA; Wistuba II
Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
[TBL] [Abstract][Full Text] [Related]
36. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
37. PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research.
Zhang Y; Mou GZ; Li TZ; Xu WT; Zhang T; Xue H; Zuo WB; Li YN; Luo YH; Jin CH
Technol Cancer Res Treat; 2021; 20():15330338211004942. PubMed ID: 33759637
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm.
Breimer LH; Nousios P; Olsson L; Brunnström H
Scand J Clin Lab Invest; 2020 Sep; 80(5):360-369. PubMed ID: 32238062
[TBL] [Abstract][Full Text] [Related]
39. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade.
Shergold AL; Millar R; Nibbs RJB
Pharmacol Res; 2019 Jul; 145():104258. PubMed ID: 31063806
[TBL] [Abstract][Full Text] [Related]
40. Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy.
Makuku R; Khalili N; Razi S; Keshavarz-Fathi M; Rezaei N
J Immunol Res; 2021; 2021():6661406. PubMed ID: 33681388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
